

1251750

NO DRAWINGS

- (21) Application No. 48802/69 (22) Filed 3 Oct. 1969
 (31) Convention Application No. 775131 (32) Filed 12 Nov. 1968 in
 (33) United States of America (US)
 (45) Complete Specification published 27 Oct. 1971
 (51) International Classification C 07 c 61/32 69/74 A 61 k 27/00
 (52) Index at acceptance




C2C 20Y 220 226 227 22Y 290 29Y 30Y 32Y 3A10E1
 3A10E4C 3A10E5E 3A10E5F1A 3A10E5F1C
 3A10E5F2D 3A10E5F3D 3A7V2A3 3A7V2E2
 3A7V2F1 3A7V2H 3A7V2J1 3A7V2K4 3A7V2L
 3A7V2Q 3A7V4A3 3A7V4E2 3A7V4G1 3A7V4H
 3A7V4K4 3A7V4L 620 650 771 778 790 79Y ND
 NN

(54) PROSTAGLANDIN ANALOGUES AND THE MANUFACTURE THEREOF

(71) We, THE UPJOHN COMPANY, a corporation organized and existing under the laws of the State of Delaware, United States of America, of 301 Henrietta Street, Kalamazoo, State of Michigan, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—


This invention relates to novel compounds having prostaglandin F β -type biological properties and to methods for producing them. In particular this invention relates to novel compounds of the formula:—



II

wherein R₁, R₂, and R₃ are as defined above, with the same proviso relative to R₂ and R₃ and p is 3 or 5.


This invention also relates to novel compounds of the formula:—



I

wherein R₁ is hydrogen, alkyl of one to 8 carbon atoms, inclusive, or a pharmacologically acceptable cation, R₂ and R₃ are hydrogen or alkanoyl of one to 8 carbon atoms, inclusive, with the proviso that when R₂ is alkanoyl, R₃ is also alkanoyl, m is zero or 2, and Z is —CH₂CH₂— or cis—CH=CH—.

This invention also relates to novel compounds of the formula:—



III

wherein p, R₁, R₂, and R₃ are as defined above, with the same proviso relative to R₂ and R₃.

When R₂ and R₃ in a compound of formula I, II, or III are both alkanoyl, those can be the same or different.

Examples of alkyl of one to 8 carbon atoms are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, and isomeric forms thereof.

Examples of alkanoyl of one to 8 carbon atoms, inclusive, are formyl, acetyl, propionyl, butyryl, valeryl, hexanoyl, heptanoyl, octanoyl, and isomeric forms thereof.

Pharmacologically acceptable cations with—

[Price 25p]

BEST AVAILABLE COPY


in the scope of R_1 in formulas I, II, and III are quaternary ammonium ions or the cationic form of a metal, ammonia, or an amine.

- Especially preferred metal cations are those derived from the alkali metals, e.g., lithium, sodium, and potassium, and from the alkaline earth metals, e.g., magnesium and calcium, although cationic forms of other metals, e.g., aluminium, zinc, and iron, are within the scope of this invention.


- Pharmacologically acceptable amine cations within the scope R_1 in formulas I, II, and III are those derived from primary, secondary, or tertiary amines. Examples of suitable amines are methylamine, dimethylamine, trimethylamine, ethylamine, dibutylamine, triisopropylamine, N-methylhexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, dicyclohexylamine, benzylamine, dibenzylamine, α -phenylethylamine, β -phenylamine, ethylenediamine, and diethylenetriamine, and like aliphatic, cycloaliphatic, and araliphatic amines containing up to and including about 18 carbon atoms, as well as heterocyclic amines, e.g., piperidine, morpholine, pyrrolidine, piperazine, and lower-alkyl derivatives thereof, e.g., 1-methylpiperidine, 4-ethylmorpholine, 1-isopropylpyrrolidine, 2-methylpyrrolidine, 1,4-dimethylpiperazine, and 2-methylpiperidine, as well as amines containing water-solubilizing or hydrophilic groups, e.g., mono-, di-, and triethanolamine, ethyldiethanolamine, N-butylethanolamine, 2-amino-1-butanol, 2-amino-2-ethyl-1,3-propanediol, 2-amino-2-methyl-1-propanol, tris(hydroxymethyl)aminomethane, N-phenylethanolamine, N-(*p*-tert-amyphenyl)diethanolamine, galactamine, N-methylglucamine, N-methylglucosamine, ephedrine, phenylephrine, epinephrine, and procaine.

- Examples of suitable pharmacologically acceptable quaternary ammonium cations within the scope of R_1 in formulas I, II, and III are tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, and phenyltriethylammonium.

- The novel compounds of formulas I, II, and III are somewhat similar to certain of the known prostaglandins. The latter are considered to be derivatives of prostanoic acid which has the following structure:



- The known prostanoic acid derivative, prostaglandin $F_{2\alpha}$ ($PGF_{2\alpha}$), has the following structure.



The compound of formula I wherein R_1 , R_2 , and R_3 are hydrogen, and Z is $-\text{CH}_2\text{CH}_2-$, has the same structure as $PGF_{2\alpha}$ except that this novel formula I compound has one less carbon atom in the hydroxy-containing side chain (ω -nor) when m is zero, and one more carbon atom in the same chain (ω -homo) when m is 2. The other compounds encompassed by formula I, i.e., when Z is $\text{cis}-\text{CH}=\text{CH}-$, are similarly related to the known prostanoic acid derivative $PGF_{2\alpha}$. The compound of formula II wherein R_1 , R_2 , and R_3 are hydrogen and p is 3 has one less carbon (ω -nor) than the known $PGF_{1\alpha}$. The compound of formula III wherein R_1 , R_2 , and R_3 are hydrogen has one less carbon atom (ω -nor) than the known dihydro- $PGF_{1\alpha}$ when p is 3, and one more carbon atom (ω -homo) when p is 5.

These novel ω -nor and ω -homo PGF_n compounds of formula I, II, and III are extremely potent in causing various biological responses of the general type caused by the known PGF_n compounds. For that reason, these novel formula I, II, and III compounds are useful for pharmacological purposes. Examples of those biological responses are pressor activity as measured, for example, in anesthetized (pentobarbital sodium) pentolinium-treated rats with indwelling aortic and right heart cannulas; stimulation of smooth muscle as shown, for example, by tests on strips of guinea pig ileum, rabbit duodenum, or gerbil colon; activity on the central nervous system; inhibition of gastric secretion as shown in dogs with secretion stimulated by food or histamine infusion; decrease of blood platelet adhesiveness as shown by platelet-to-glass adhesiveness, and inhibition of blood platelet aggregation and thrombus formation induced by various physical stimuli, e.g., arterial injury, and various biochemical stimuli, e.g., ADP, ATP, serotonin, thrombin, and collagen.

Because of these biological responses, these novel formula I, II, and III prostaglandins are useful to study, prevent, control, or alleviate a wide variety of diseases and undesirable physiological conditions in birds and mammals, including humans, useful domestic animals, pets, and zoological specimens, and in laboratory animals, for example, mice, rats, rabbits, and monkeys.

For example, these novel formula I, II, and III compounds are useful in place of oxytocin to induce labor in pregnant animals, including man, cows, sheep, and pigs, at or near term, or in pregnant animals with intra-uterine death of the fetus from about 20 weeks

to term. For this purpose, the compound is preferably infused intravenously at a dose 0.01 to 50 $\mu\text{g.}$ per kg. of body weight per minute until or near the termination of the second stage of labor, i.e., expulsion of the fetus. These compounds are especially useful when the female is one or more weeks post-mature and natural labor has not started, or 12 to 60 hours after the membranes have ruptured and natural labor has not yet started.

The novel formula I, II, and III compounds of this invention are useful in mammals, including man, as nasal decongestants. For this purpose, the compounds are used in a dose range of 10 $\mu\text{g.}$ to 10 mg. per ml. of a pharmacologically suitable liquid vehicle or as an aerosol spray, both for topical application.

The novel formula I, II, and III compounds not only are potent in causing smooth muscle stimulation, but also are highly active in potentiating other known smooth muscle stimulators, for example, oxytocin, vasopressin, and the various ergot alkaloids including derivatives and analogs thereof. For this reason, these novel compounds are useful in place of or in combination with less than the usual amounts of these known smooth muscle stimulators, for example, to relieve the symptoms of paralytic ileus, to control or prevent atonic uterine bleeding after abortion or delivery, to aid in the expulsion of the placenta, and during the puerperium. For these purposes, these novel formula I, II, and III compounds are preferably first administered by intravenous infusion at a dose in the range 0.01 to 50 $\mu\text{g.}$ per kg. of body weight per minute until the desired effect is obtained. Subsequent doses are given by intravenous, subcutaneous, or intramuscular injection or infusion in the range 0.01 to 2 mg. per kg. of body weight per day.

These novel formula I, II, and III compounds are also useful for controlling the reproductive cycle in ovulating female mammals, including humans and animals such as monkeys, rats, rabbits, dogs, and cattle. For that purpose, the compounds are administered systemically at a dose level in the range 0.01 mg. to 20 mg. per kg. of body weight of the female mammal, advantageously during a span of time starting approximately at the time of ovulation and ending approximately at the time of menses or just prior to menses, thus insuring a non-pregnant cycle notwithstanding ovulation and contact with a fertile male.

These novel formula I, II, and III compounds are useful as hypotensive agents to reduce blood pressure in mammals, including man. For this purpose, the compounds are preferably administered by intravenous infusion at the rate 0.01 to about 50 $\mu\text{g.}$ per kg. of body weight per minute, or in single or multiple doses of 25 to 500 $\mu\text{g.}$ per kg. of body weight total per day.

These novel formula I, II, and III com-

pounds are useful in mammals, including man and certain useful animals, e.g., dogs and pigs, to reduce and control excessive gastric secretion, thereby reducing or avoiding gastrointestinal ulcer formation, and accelerating the healing of such ulcers already present in the gastrointestinal tract. For this purpose, the compounds are injected or infused intravenously, subcutaneously, or intramuscularly in an infusion dose range 0.1 $\mu\text{g.}$ to 50 $\mu\text{g.}$ per kg. of body weight per minute, or in a total daily dose by injection or infusion in the range 0.1 to 20 mg. per kg. of body weight per day.

These novel formula I, II, and III compounds are useful whenever it is desired to inhibit platelet aggregation, to reduce the adhesive character of platelets, and to remove or prevent the formation of thrombi in mammals, including man, rabbits, and rats. For example, these compounds are useful in the treatment and prevention of myocardial infarcts, to treat and prevent post-operative thrombosis, to promote patency of vascular grafts following surgery, and to treat conditions such as atherosclerosis, arteriosclerosis, blood clotting defects due to lipemia, and other clinical conditions in which the underlying etiology is associated with lipid imbalance or hyper-lipidemia. For these purposes, these compounds are administered systemically, e.g., intravenously, subcutaneously, intramuscularly, and in the form of sterile implants for prolonged action. For rapid response, especially in emergency situations, the intravenous route of administration is preferred. Doses in the range 0.005 to 20 mg. per kg. of body weight per day are preferred.

These novel formula I, II, and III compounds are especially useful as additives to blood, blood products, blood substitutes, and other fluids which are used in artificial extracorporeal circulation and perfusion of isolated body portions, e.g., limbs and organs, whether attached to the original body, detached and being preserved or prepared for transplant, or attached to a new body. During these circulations and perfusions, aggregated platelets tend to block the blood vessels and portions of the circulation apparatus. This blocking is avoided by the presence of these compounds. For this purpose, the compound is added gradually or in single or multiple portions to the circulating blood, to the blood of the donor animal, to the perfused body portion, attached or detached, to the recipient, or to two or all of those at a total steady state dose of .001 to 10 mg. per liter of circulating fluid. It is especially useful to use these compounds in laboratory animals, e.g., cats, dogs, rabbits, monkeys, and rats, for these purposes in order to develop new methods and techniques for organ and limb transplants.

These novel formula I, II, and III com-

70

75

80

85

90

95

100

105

110

115

120

125

130

pounds and also the other known PGF_2 compounds increase the flow of blood in the mammalian kidney, thereby increasing volume and electrolyte content of the urine. Therefore, these compounds are useful in managing cases of renal disfunction, especially those involving blockage of the renal vascular bed. Illustratively, the compounds are useful to alleviate and correct cases of edema resulting, for example, from massive surface burns, and in the management of shock. For these purposes, the compounds are preferably first administered by intravenous injection at a dose in the range 10 to 1000 μg . per kg. of body weight or by intravenous infusion at a dose in the range 0.1 to 20 μg . per kg. of body weight per minute until the desired effect is obtained. Subsequent doses are given by intravenous, intramuscular, or subcutaneous injection or infusion in the range 0.05 to 2 mg. per kg. of body weight per day.

In spite of the apparent similarities of structure between the novel compounds of formulas I, II, and III, and the known PGF_2 compounds, i.e., dihydro- $\text{PGF}_{1,2}$, $\text{PGF}_{1,2}$, $\text{PGF}_{2,2}$, and $\text{PGF}_{3,2}$, the novel formula I, II, and III compounds are surprisingly and quite unexpectedly more useful for one or more of the above illustrative purposes than the known PGF_2 compounds. The known PGF_2 compounds uniformly cause multiple responses even at low doses. For example, $\text{PGF}_{1,2}$ causes smooth muscle stimulation and a blood pressure decrease at the same time that it acts to increase nasal patency. In striking contrast, the novel formula I, II, and III compounds each are more specific in causing $\text{PGF}_{1,2}$ -type biological responses. Each of these novel compounds is therefore surprisingly and unexpectedly more useful for the pharmacological purposes indicated above because each has a different and narrower spectrum of biological activity than the natural PGF_2 compounds, causing smaller and fewer undesired side effects than the natural compounds.


For the above purposes, the novel formula I, II, and III compounds of this invention are administered in various ways. For example, as mentioned above, topical administration is the preferred route when the compound is used to promote nasal patency in cases of nasal congestion. Systemic administration, e.g., intravenous, subcutaneous, intramuscular, oral, rectal, vaginal, buccal, sublingual, and as sterile implants for prolonged action, are preferred for the other pharmacological purposes mentioned above.

For intravenous injection or infusion, sterile aqueous isotonic solutions are preferred. For that purpose, it is preferred because of increased water solubility that R_1 in the formula I, II, or III compound be hydrogen or a pharmacologically acceptable cation. For subcutaneous or intramuscular injection, sterile solutions or suspensions of the acid salt, or


ester form in aqueous or non-aqueous media are used. Tablets, capsules, and liquid preparations such as syrups, elixirs, and simple solutions, with the usual pharmaceutical carriers, are used for oral, buccal, or sublingual administration. For rectal or vaginal administration, suppositories or powders prepared as known in the art are used. For tissue implants, a sterile tablet or silicone rubber capsule containing the substance is used.

According to the present invention therefore there is also provided a therapeutic composition comprising as the active ingredient one of the novel compounds of the invention together with a pharmaceutically acceptable carrier.


The novel compounds of formula I are prepared by reducing the carbonyl group of the corresponding compounds of the formula:



Similarly, the novel compounds of formula II are prepared by reducing the carbonyl group of the corresponding compounds of the formula:



Similarly, the novel compounds of formula III are prepared by reducing the carbonyl group of the corresponding compounds of the formula:



In formulas VI, VII, and VIII, R_2 , R_3 , m , p , and Z are as defined above, and R_1 is hydrogen or alkyl of one to 8 carbon atoms, inclusive.

These formula VI, VII, and VIII ketone intermediates are known in the art or are prepared by methods known in the art. See Beerthuis et al., *Rec. Trav. Chim.* 87, 461 (1968) for the compounds of formula VI wherein R_2 and R_4 are hydrogen, m is zero or 2, and Z is $-\text{CH}_2\text{CH}_2-$, and for the compound of formula VII wherein R_2 and R_4 are hydrogen.

The formula VI compounds wherein R_2 and R_4 are hydrogen, m is zero or 2, and Z is $\text{cis}-\text{CH}=\text{CH}-$, are prepared from 5,8,11,14,17-nonadecapentaenoic acid ($m=0$) and 5,8,11,14,17-heneicosapentaenoic acid ($m=2$) as described by Struijk et al., *Rec. Trav. Chim.* 85, 1233 (1966), for the production of PGE_2 from 5,8,11,14,17-eicosapentaenoic acid. These C-19 and C-21 pentaenoic acids are prepared by saponification of the corresponding methyl esters which are prepared as described by the combination of Van der Steen et al., *Rec. Trav. Chim.* 82, 1015 (1963) and Pabon et al., *Rec. Trav. Chim.* 84, 1319 (1965), using in place of the initial reactant of Pabon et al., i.e., 1-bromo-2-pentyne, 1-bromo-2-butyne (C-19) and 1-bromo-2-hexyne (C-21). The latter two reactants are prepared from the corresponding known acetylenic alcohols by reaction with PBr_2 .

The formula VIII compound wherein R_2 and R_4 are hydrogen is prepared by reduction of the carbon-carbon double bonds of any of the formula VI compounds wherein R_2 and R_4 are hydrogen, and Z is $-\text{CH}_2\text{CH}_2-$ or $\text{cis}-\text{CH}=\text{CH}-$. Alternatively, reduction of the carbon-carbon double bond of the formula VII compound wherein R_2 and R_4 are hydrogen leads to the corresponding formula VIII compound wherein R_2 and R_4 are hydrogen and p is 3. An alternative method for producing the formula VIII compound wherein R_2 and R_4 are hydrogen, and p is 5, is reduction of the carbon-carbon double bond of ω -homo- PGE_1 , a known compound. See Beerthuis et al., cited above.

The novel formula I, formula II, and formula III compounds of this invention wherein R_1 is alkyl are prepared by carbonyl reduction of the corresponding alkyl esters of the formula VI, VII, or VIII ketone intermediates. These alkyl esters are prepared by esterification of the corresponding formula VI, VII, or VIII ketone intermediates wherein R_1 is hydrogen. Alternatively, the formula I, II, or III alkyl esters are prepared by esterification of the corresponding formula I, II, or III acids, i.e., wherein R_1 is hydrogen.

The novel formula I, formula II, and formula III compounds of this invention wherein R_1 is a pharmacologically acceptable cation are preferably prepared by transformation of the corresponding formula I, II, or III free acid ($R_{11}=\text{H}$) to the desired salt.

The novel formula I, formula II, and formula III compounds of this invention

wherein both R_2 are alkanoyl are prepared by carbonyl reduction of the corresponding alkanoyl derivatives of the formula VI, VII, or VIII ketone intermediates wherein both R_2 are alkanoyl. This produces a formula I, II, or III dialkanoyl compound wherein R_3 is hydrogen. These dialkanoyl formula VI, VII, and VIII ketone intermediates are prepared by acylation of the corresponding formula VI, VII, or VIII ketone intermediate wherein both R_2 are hydrogen.

When it is desired that R_3 in the novel formula I, formula II, or formula III compounds of this invention be alkanoyl, the formula I, II, or III compound wherein R_3 is hydrogen is acylated. When both R_2 in the formula I, II, or III compound are alkanoyl, the R_3 alkanoyl introduced can be the same or different as the R_2 alkanoyls. When both R_2 in the formula I, II, or III compound are hydrogen, acylation changes all three hydroxy groups to the same alkanoyloxy group.

In a formula I, formula II, or formula III compound, when R_1 is to be alkyl and R_2 and/or R_3 are to be alkanoyl, either or both the alkyl and the alkanoyls are added before or after the carbonyl reduction of the formula VI, VII, or VIII ketone intermediate.

An alternative method for producing formula III compounds is reduction of the carbon-carbon double bonds of the corresponding formula I or II compound.

Carbonyl reduction to produce the novel formula I, formula II, and formula III compounds of this invention wherein R_2 is hydrogen is carried out by reaction the corresponding keto intermediates of formulas VI, VII, and VIII with any carbonyl reducing agent which does not react with the ester group or the carbon-carbon double bonds. Examples of such reducing agents are sodium or potassium borohydride and lithium aluminium (tri-tert-butoxy)hydride.

These carbonyl reductions are carried out by methods known in the art for comparable reductions of prostanoic acid derivatives. See, for example, Bergström et al., *Acta Chem. Scand.* 16, 969 (1962) and Anggard et al., *J. Biol. Chem.* 239, 4101 (1964). Lower alkanols, e.g., methanol and ethanol, are preferred as reaction solvents, although other solvents, e.g., dioxane and diethylene glycol dimethyl ether are also used, especially in combination with the lower alkanol.

Although 0.25 molecular equivalent of the borohydride or lithium aluminium (tri-tert-butoxy-hydride) reducing agent is sufficient to reduce one molecular equivalent of the formula VI, formula VII, or formula VIII ketone reactant, it is preferred to use an excess of the reducing agent, preferably 1 to 15 molecular equivalents of reducing agent per molecular equivalent of the ketone reactant. It is preferred to add a solution or suspension of the reducing agent to the ketone re-

actant, although the reverse order can also be used. A reaction temperature in the range 0° to 50° C. is usually satisfactory. At about 25° C., the desired reaction is usually complete in 0.5 to 2 hours. The resulting complex compound is then transformed to the desired product in the usual manner by treatment with aqueous acid, advantageously dilute hydrochloric acid.

The desired formula I, formula II, or formula III reduction product is isolated by conventional techniques, for example, evaporation of the reaction solvent and extraction of the residual aqueous mixture with a water-immiscible solvent, for example, diethyl ether. Evaporation of the latter solvent then gives the desired product.

These borohydride or lithium aluminium (tri-tert-butoxy)-hydride reductions of the formula VI, VII, and VIII keto reactants each produce a mixture of a beta-hydroxy compound and an isomeric (epimeric) alpha-hydroxy compound. The beta and alpha components of these mixtures of isomeric hydroxy compounds are separated from each other by methods known in the art for the separation of analogous pairs of isomeric prostanoid acid derivatives. See, for example, Bergström et al., cited above, Granström et al., *J. Biol. Chem.* 240, 457 (1965), and Gréen et al., *J. Lipid Research* 5, 117 (1964). Especially preferred as separation methods are partition chromatographic procedures, both normal and reversed phase, thin layer chromatography, and countercurrent distribution procedures.

Catalytic hydrogenation or diimide are used to reduce carbon-carbon double bonds in the various unsaturated intermediates used to produce formula III compounds.

For catalytic hydrogenation, palladium catalysts, especially on a carbon carrier, are preferred. It is also preferred that the hydrogenation be carried out in the presence of an inert liquid diluent, for example, methanol, ethanol, dioxane, and ethyl acetate. Hydrogenation pressures ranging from atmospheric to 50 p.s.i., and hydrogenation temperatures ranging from 10° to 100° C. are preferred. The reduced formula III acid or ester is isolated from the hydrogenation reaction mixture by conventional methods, for example, removal of the catalyst by filtration or centrifugation, followed by evaporation of the solvent. The desired hydrogenation product is purified by conventional techniques, advantageously by methods known to be useful for purification of the prostaglandins, especially thin layer chromatography. See, for example, Gréen et al., cited above.

For diimide reduction, the general procedure described by van Tamelen et al., *J. Am. Chem. Soc.*, 83, 3726 (1961) is used. See also Fieser et al., "Topics in Organic Chemistry," Reinhold Publishing Corp., New York, pp. 432-434 (1963) and references cited therein

for useful general procedures. The unsaturated acid or ester reactant is mixed with a salt of azodiformic acid, preferably an alkali metal salt such as the disodium or dipotassium salt, in the presence of an inert diluent, preferably a lower alkanol such as methanol or ethanol, and preferably in the absence of substantial amounts of water. At least one molecular equivalent of the azodiformic acid salt is used for each molecular equivalent of the reactant. The resulting suspension is then stirred, preferably with exclusion of oxygen, and the mixture is made acid, advantageously with a carboxylic acid such as acetic acid. When an acid deactant is used, that acid also serves to acidify an equivalent amount of the azodiformic acid salt. A reaction temperature in the range 10° to 40° C. is usually suitable. Within that temperature range, the reaction is usually complete within less than 24 hours. The desired reduced product is then isolated by conventional methods, for example, evaporation of the diluent, followed by separation from inorganic materials by solvent extraction. The product is purified, if desired, as described above.

Esterification of the formula I, II, or III acids or any of the other acid reactants is carried out by interaction of the acid with the appropriate diazohydrocarbon. For example, when diazomethane is used, the methyl esters are produced. Similar use of diazoethane, diazobutane, and 1-diazo-2-ethylhexane, for example, gives the ethyl, butyl, and 2-ethylhexyl esters, respectively.

Esterification with diazohydrocarbons is carried out by mixing a solution of the diazohydrocarbon in a suitable inert solvent, preferably diethyl ether, with the acid reactant, advantageously in the same or a different inert diluent. After the esterification reaction is complete, the solvent is removed by evaporation, and the ester purified if desired by conventional methods, preferably by chromatography. It is preferred that contact of the acid reactants with the diazohydrocarbon be no longer than necessary to effect the desired esterification, preferably one to ten minutes, to avoid undesired molecular changes. Diazohydrocarbons are known in the art or are prepared by methods known in the art. See, for example, *Organic Reactions*, John Wiley & Sons, Inc., New York, N.Y., Vol. 8, pp. 389-394 (1954).

An alternative method for esterification comprises transformation of the free acid to the corresponding silver salt, followed by interaction of that salt with an alkyl iodide. Examples of suitable iodides are methyl iodide, ethyl iodide, butyl iodide, isobutyl iodide, and tert-butyl iodide. The silver salts are prepared by conventional methods, for example, by dissolving the acid in cold dilute aqueous ammonia, evaporating the excess

amonia at reduced pressure, and then adding the stoichiometric amount of silver nitrate.

Carboxyacylation of the hydroxy moieties in the keto reactants or in the formula I, II, or III hydroxy compounds is accomplished by interaction of the hydroxy compound with a carboxyacylating agent, preferably the anhydride of an alkanolic acid of one to 8 carbon atoms, inclusive. For example, use of acetic anhydride gives the corresponding diacetate. Similar use of propionic anhydride, isobutyric anhydride, and hexanoic acid anhydride gives the corresponding carboxyacylates.

The carboxyacylation is advantageously carried out by mixing the hydroxy compound and the acid anhydride, preferably in the presence of a tertiary amine such as pyridine or triethylamine. A substantial excess of the anhydride should be used, preferably 10 to 10,000 moles of anhydride per mole of the hydroxy compound reactant. The excess anhydride serves as a reaction diluent and solvent. An inert organic diluent, for example, dioxane, can also be added. It is preferred to use enough of the tertiary amine to neutralize the carboxylic acid produced by the reaction, as well as any free carboxyl groups present in the hydroxy compound reactant.

The carboxyacylation reaction is preferably carried out in the range 0° to 100° C. The necessary reaction time will depend on such factors as the reaction temperature, and the nature of the anhydride and tertiary amine reactants. With acetic anhydride, pyridine, and a 25° C. reaction temperature, a 12 to 24-hour reaction time is used.

The carboxyacylated product is isolated from the reaction mixture by conventional methods. For example, the excess anhydride is decomposed with water, and the resulting mixture acidified and then extracted with a solvent such as diethyl ether. The desired carboxyacylate is recovered from the diethyl ether extract by evaporation. The carboxyacylate is then purified by conventional methods, advantageously by chromatography.


The formula I, II, or III acids ($R_1 = \text{hydrogen}$) are transformed to pharmacologically acceptable salts by neutralization with appropriate amounts of the corresponding inorganic or organic base, examples of which correspond to the cations and amines listed above. These transformations are carried out by a variety of procedures known in the art to be generally useful for the preparation of inorganic, i.e., metal or ammonium, salts, amine acid addition salts, and quaternary ammonium salts. The choice of procedure depends in part upon the solubility characteristics of the particular salt to be prepared. In the case of the inorganic salts, it is usually suitable to dissolve the formula I, II, or III acid in water containing the stoichiometric amount of a hydroxide, carbonate, or bicarbon-

ate corresponding to the inorganic salt desired. For example, such use of sodium hydroxide, sodium carbonate, or sodium bicarbonate gives a solution of the sodium salt of the prostanoic acid derivative. Evaporation of the water or addition of a water-miscible solvent of moderate polarity, for example, a lower alkanol or a lower alkanone, gives the solid inorganic salt if that form is desired.

To produce an amine salt, the formula I, II, or III acid is dissolved in a suitable solvent of either moderate or low polarity. Examples of the former are ethanol, acetone, and ethyl acetate. Examples of the latter are diethyl ether and benzene. At least a stoichiometric amount of the amine corresponding to the desired cation is then added to that solution. If the resulting salt does not precipitate, it is usually obtained in solid form by addition of a miscible diluent of low polarity or by evaporation. If the amine is relatively volatile, any excess is easily removed by evaporation. It is preferred to use stoichiometric amounts of the less volatile amines.

Salts wherein the cation is quaternary ammonium are produced by mixing the formula I, II, or III acid with the stoichiometric amount of the corresponding quaternary ammonium hydroxide in water solution, followed by evaporation of the water.

Also in British Patent Specification No. 1,198,071 there is described and claimed an optically active compound of the formula:—



wherein is a generic expression denoting an alpha or beta configuration for the attached moiety, R_{11} is hydrogen, alkyl of 1 to 8 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 10 carbon atoms inclusive, phenyl, or phenyl substituted by 1 to 3 chloro or alkyl of 1 to 4 carbon atoms, inclusive, R_2 is hydrogen or alkyl of 1 to 8 carbon atoms, inclusive, R_3 and R_4 are hydrogen or alkyl of 1 to 4 carbon atoms, inclusive, and C_nH_{2n} is alkylene of 1 to 8 carbon atoms, inclusive, and pharmacologically acceptable salts thereof when R_1 is hydrogen, excluding the compounds known as $PGF_{1\alpha}$ and $PGF_{1\beta}$ and their salts and esters; a compound of the above formula wherein C_nH_{2n} is hexamethylene; a compound of the above formula wherein R_4 is hydrogen; a compound of the above formula wherein R_3 is

hydrogen; a compound of the above formula wherein R_1 is alkyl of 1 to 4 carbon atoms inclusive; a compound of the above formula wherein R_1 is methyl; a compound of the above formula wherein R_1 is hydrogen; a compound of the above formula wherein the $-C_nH_{2n}-COOR_1$ moiety is attached in alpha configuration and a compound of the above formula wherein the $-OH$ adjacent to the $-C_nH_{2n}-COOR_1$ is attached in beta configuration.

The invention is more fully understood by the following examples.

EXAMPLE 1

15 ω -nor-PGF_{2,2} (formula I: R_1, R_2 and $R_3 = H$, $m=O$, $Z=-CH_2CH_2-$).

A suspension of sodium borohydride (900 mg.) in 100 ml. of methanol at 5° to 10° C is added gradually with stirring during 2 minutes to a solution of ω -nor-PGE₂ (300 mg.) in 30 ml. of methanol at 0° to 5° C. Stirring is continued at 0° to 5° C. for 20 minutes. The reaction mixture is then allowed to warm to 25° C., and is stirred at that temperature for one hour. The resulting mixture is then concentrated by evaporation to 2/3 of its original volume, mixed with 25 ml. of water, and evaporated further to remove the methanol. The aqueous solution which results is acidified with dilute hydrochloric acid and extracted three times with diethyl ether. The diethyl ether extracts are combined, washed with water, dried, and evaporated to give a mixture of the beta and alpha epimers of ω -nor-PGF₂.

The mixture of epimeric acids is subjected to reversed phase partition chromatography on silanized diatomaceous earth (Gas Chrom CLZ 100/120 mexh, a product of Applied Science Labs., State College, Pa.), using methanol-water (516 ml.—684 ml.) as the mobile phase and isooctanol-chloroform (60 ml.—60 ml.) as the stationary phase. The column support (500 g.) is mixed with 45 ml. of stationary phase, and is then packed into column form as a slurry with mobile phase. The mixture of epimeric ω -nor-PGF₂ acids is dissolved in 15 ml. of stationary phase and mixed with an additional 12 g. of the column support. The resulting slurry is poured on to the column. The column is then eluted with mobile phase, 50-ml. fractions of eluate being collected. The eluate fractions containing the beta epimer, as shown by smooth muscle assays, are combined and evaporated to give ω -nor-PGF_{2,2}.

Following the procedure of Example 1, but using in place of the ω -nor-PGE₂, ω -nor-PGE₁, ω -nor-dihydro-PGE₁, ω -nor-PGE₃, ω -homo-PGE₁, ω -homo-PGE₂, ω -homo-dihydro-PGE₁, ω -homo-PGE₂, the methyl esters of each of those and also of ω -nor-PGE₂, the diacetates of each of those and also of ω -nor-PGE₂, and the methyl ester diacetates of each

of those and also of ω -nor-PGE₂, there are obtained ω -nor-PGF_{1,1}, ω -nor-dihydro-PGF_{1,1}, ω -nor-PGF_{3,3}, ω -homo-PGF_{1,1}, ω -homo-PGF_{2,2}, ω -homo-dihydro-PGF_{1,1}, ω -homo-PGF_{2,2}, the methyl esters of each of those PGF_n analogues and also of ω -nor-PGF_{2,2}, the diacetates of each of those PGF_n analogues and also of ω -nor-PGF_{2,2}, and the methyl ester diacetates of each of those PGF_n analogues and also of ω -nor-PGF_{2,2}, respectively.

EXAMPLE 2

ω -nor-PGF_{2,2} methyl ester (formula I: $R_1 = \text{methyl}$, R_2 and $R_3 = H$, $m=O$, $Z=-CH_2CH_2-$).

ω -nor-PGF_{2,2} (10 mg.) is dissolved in a mixture of methanol and diethyl ether (1:1). A diethyl ether solution of diazomethane (1 g.) is added, and the mixture is allowed to stand at about 25° for 5 minutes. The reaction mixture is then evaporated to dryness to give the methyl of ω -nor-PGF_{2,2}.

Following the procedure of Example 2 but using in place of diazomethane, diazoethane, diazobutane, and 1-diazo-2-ethyl-hexane, there are obtained the ethyl, butyl, and 2-ethylhexyl esters, respectively.

Also following the procedure of Example 2, ω -nor-PGF_{1,1}, ω -nor-dihydro-PGF_{1,1}, ω -nor-PGF_{3,3}, ω -homo-PGF_{1,1}, ω -homo-PGF_{2,2}, ω -homo-dihydro-PGF_{1,1}, ω -homo-PGF_{2,2}, the diacetates and triacetates of each of those and also of ω -nor-PGF_{2,2}, are each transformed to the corresponding methyl, ethyl, butyl, and 2-ethylhexyl esters.

EXAMPLE 3

ω -nor-PGF_{2,2} triacetate (formula I: $R_1 = H$, R_2 and $R_3 = \text{acetyl}$, $m=O$, $Z=-CH_2CH_2-$).

ω -nor-PGF_{2,2} (10 mg.) is mixed with acetic anhydride (3 ml.) and pyridine (3 ml.), and the mixture is allowed to stand at 25° C. for 18 hours. The reaction mixture is then cooled with ice, diluted with water, and acidified with dilute hydrochloric acid to pH 1. The mixture is then extracted three times with diethyl ether. The diethyl ether extracts are combined, and washed successively with dilute hydrochloric acid, dilute aqueous sodium bicarbonate solution, and water. The diethyl ether is then evaporated to give ω -nor-PGF_{2,2} triacetate.

Following the procedure of Example 3, but replacing the acetic anhydride with propionic anhydride, isobutyric anhydride, and hexanoic acid anhydride, the corresponding tricarboxyacyl derivatives of ω -nor-PGF_{2,2} were obtained.

Also following the procedure of Example 3, ω -nor-PGF_{1,1}, ω -nor-dihydro-PGF_{1,1}, ω -nor-PGF_{3,3}, ω -homo-PGF_{1,1}, ω -homo-PGF_{2,2}, ω -homo-dihydro-PGF_{1,1}, ω -homo-PGF_{2,2}, and the methyl esters of each of those and also of ω -nor-PGF_{2,2} are each transformed to the cor-

responding triacetates, tripropionates, triisobutyrate, and trihexanoates.

Also following the procedure of Example 3, the diacetates of ω -nor-PGF_{1 β} , ω -nor-dihydro-PGF_{1 β} , ω -nor-PGF_{2 β} , ω -nor-PGF_{3 β} , ω -homo-dihydro-PGF_{1 β} , ω -homo-PGF_{1 β} , ω -homo-PGF_{2 β} , and ω -homo-PGF_{3 β} are each transformed to the corresponding triacetates, propionates-diacetates, butyrate-diacetates, and hexanoate-diacetates.

EXAMPLE 4

ω -nor-PGF_{2 β} sodium salt (Formula I:
R₁=Na⁺, R₂ and R₃=H, m=O,
Z=—CH₂CH₂—).

ω -nor-PGF_{2 β} (10 mg.) is dissolved in 10 ml. of water-ethanol (1:1). The solution is cooled to about 10°C., and is neutralized with an equivalent amount of 0.1 N aqueous sodium hydroxide solution. Evaporation to dryness gives ω -nor-PGF_{2 β} sodium salt.

Following the procedure of Example 4 but using potassium hydroxide, calcium hydroxide, tetramethylammonium hydroxide, and benzyltrimethylammonium hydroxide, in place of sodium hydroxide there are obtained the corresponding salts of ω -nor-PGF_{2 β} .

Also following the procedure of Example 4, each of the other PGF _{β} analogues and the diacyl and triacyl PGF _{β} analogues mentioned above are transformed to the corresponding sodium, potassium, calcium, tetramethylammonium, and benzyltrimethylammonium salts.

EXAMPLE 5

ω -nor-dihydro-PGF_{1 β} (formula III:

R₁, R₂, and R₃=H, p=3).

A solution of ω -nor-PGF_{1 β} (100 mg.) in 8 ml. of ethyl acetate is shaken with hydrogen at about one atmosphere pressure and 25°C. in the presence of 5% palladium on charcoal (15 mg.). One equivalent of hydrogen is adsorbed in about 100 minutes. The hydrogenation is stopped, and the catalyst is removed by filtration. Evaporation of the filtrate gives a gummy residue which is chromatographed on silica gel with ethyl acetate and hexane (3:1) to give ω -nor-dihydro-PGF_{1 β} .

Following the procedure of Example 5, ω -nor-PGF_{2 β} and ω -nor-PGF_{3 β} are each transformed to ω -nor-dihydro-PGF_{1 β} , using 2 and 3 equivalents of hydrogen, respectively.

Also following the procedure of Example 5, ω -homo-PGF_{1 β} , ω -homo-PGF_{2 β} , and ω -homo-PGF_{3 β} are each transformed to ω -homo-dihydro-PGF_{1 β} , using one, 2, and 3 equivalents of hydrogen, respectively.

Also following the procedure of Example 5 and using the appropriate amount of hydrogen, each of the unsaturated alkyl esters and di- and trialkanoates mentioned above is transformed to the corresponding dihydro-PGF_{1 β} analogue.

EXAMPLE 6

ω -nor-dihydro-PGF_{1 β} (formula III:


R₁, R₂, and R₃=H, p=3).

ω -nor-PGF_{1 β} (50 mg.) is dissolved in 10 ml. of absolute ethanol. Air is flushed from the reaction vessel with a stream of dry nitrogen gas, and is excluded thereafter by maintaining a slight positive pressure of nitrogen in the reaction vessel. A suspension of 50 mg. of disodium azodiformate in 5 ml. of absolute ethanol is added, and the resulting mixture is stirred at about 25°C. and made acid with a few drops of glacial acetic acid. Stirring at 25°C. is continued for 8 hours. The reaction mixture is then evaporated to dryness. The resulting residue is dissolved in a mixture of diethyl ether and water. The diethyl ether layer is separated, dried with anhydrous sodium sulfate, and evaporated at reduced pressure to give ω -nor-dihydro-PGF_{1 β} with substantially the same properties as the material prepared according to Example 5.

Following the procedure of Example 6, each of the unsaturated PGF _{β} analogues reduced according to the procedure of Example 5 is also reduced according to the procedure of Example 6 to give the corresponding dihydro-PGF_{1 β} analogue with substantially the same properties as the materials prepared according to Example 5. In those reductions, amounts of disodium azodiformate appropriate to the number of carbon-carbon double bonds are used.

WHAT WE CLAIM IS:—

1. A compound of the formula¹



wherein R₁ is hydrogen, alkyl of one to 8 carbon atoms, inclusive, or a pharmacologically acceptable cation, R₂ and R₃ are hydrogen or alkanoyl of one to 8 carbon atoms, inclusive, with the proviso that when R₃ is alkanoyl, R₂ is also alkanoyl, m is zero or 2, and Z is —CH₂CH₂— or cis—CH=CH—.

2. A compound according to claim 1 wherein R₁, R₂, and R₃ are hydrogen.

3. A compound according to claim 2 wherein Z is —CH₂CH₂—.

4. A compound according to claim 3 wherein m is zero.


5. A compound according to claim 3 wherein m is 2.

6. A compound according to claim 2 wherein Z is cis-CH=CH—.

7. A compound according to claim 6 wherein m is zero.

5 8. A compound according to claim 6 wherein m is 2.


9. A compound of the formula:



10 wherein R₁ is hydrogen, alkyl of one to 8 carbon atoms, inclusive, or a pharmacologically acceptable cation, and R₂ and R₃ are hydrogen or alkanoyl of one to 8 carbon atoms, inclusive, with the proviso that when R₃ is alkanoyl, R₂ is also alkanoyl and p is 3 or 5.

15 10. A compound according to claim 9 wherein R₁, R₂, and R₃ are hydrogen.

11. A compound of the formula:




20 wherein R₁ is hydrogen, alkyl of one to 8 carbon atoms, inclusive, or a pharmacologically acceptable cation, and R₂ and R₃ are hydrogen or alkanoyl of one to 8 carbon atoms, inclusive, with the proviso that when R₃ is alkanoyl, R₂ is also alkanoyl, and p is 3 or 5.

25 12. A compound according to claim 11 wherein R₁, R₂, and R₃ are hydrogen.

13. A compound according to claim 12 wherein p is 3.


30 14. A compound according to claim 12 wherein p is 5.

15. A process for producing a compound of the formula:




35 wherein R₂ and R₃ are hydrogen or alkanoyl of one to 8 carbon atoms, inclusive, with the proviso that when R₂ is alkanoyl, R₃ is also

alkanoyl, R₄ is hydrogen or alkyl of one to 8 carbon atoms, inclusive, and p is 3 or 5, which comprises reducing the carbon-carbon double bonds of a compound of the formula:




wherein R₂, R₃, and R₄ are as defined above, m is zero or 2, and X is trans-CH=CH— and Y and Z are —CH₂CH₂—, or X is trans-CH=CH—, Y is cis-CH=CH—, and Z is —CH₂CH₂— or cis-CH=CH—.

16. A process for producing a compound of the formula:




wherein R₂ is hydrogen or alkanoyl of one to 8 carbon atoms, inclusive, R₄ is hydrogen or alkyl of one to 8 carbon atoms, inclusive, m is zero or 2, and Z is —CH₂CH₂— or cis-CH=CH—, which comprises reducing the carbonyl group of a compound of the formula:




wherein R₂, R₄, m, and Z are as defined above.

17. A process for producing a compound of the formula:



wherein R_2 is hydrogen or alkanoyl of one to 8 carbon atoms, inclusive, R_4 is hydrogen or alkyl of one to 8 carbon atoms, and p is 3 or 5 inclusive, which comprises reducing the carbonyl group of a compound of the formula:



wherein R_2 , R_4 and p are as defined above.

18. A process for the preparation of a compound as claimed in any of claims 1 to 14 substantially as herein described with reference to the Examples.

19. A compound as claimed in any of claims 1 to 14 when prepared by a process as claimed in claims 15 to 18.

20. A therapeutic composition comprising as the active ingredient a compound as claimed in any of claims 1 to 14 or 19 together with a pharmaceutically acceptable carrier.

For the Applicants:—
GILL, JENNINGS & EVERY,
51—52 Chancery Lane,
London, W.C.2.

Printed for Her Majesty's Stationery Office, by the Courier Press, Leamington Spa, 1971.
Published by The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.